Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-01-10
2006-01-10
Wehbe, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093200, C514S04400A, C435S325000, C435S320100, C435S242000, C435S242000, C530S350000, C536S022100, C536S023100, C536S024100
Reexamination Certificate
active
06984379
ABSTRACT:
A method of providing a therapeutic effect in a human patient which comprises administering to the patient CD34+ cells obtained from cord blood. The CD34+ cells have been engineered with at least one nucleic acid sequence encoding a therapeutic agent. Such CD34+ cells may be engineered by transducing the cells with a retroviral vector including the nucleic acid sequence encoding the therapeutic agent. This method has been applied in treating newborn infants suffering from ADA deficiency.
REFERENCES:
patent: 5192553 (1993-03-01), Boyse et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5911983 (1999-06-01), Barranger et al.
Mitani et al, Philos Trans R Soc Lond B. Biol Sci, Feb. 1993, 339(1288), pp. 217-224.
Culver et al, (Immunology section) Pediatr. Res. 31 : 149 A 1992.
Anderson, W. F. Human Gene Therapy, Science, 256, May 8, 1992 808-813.
Moritz et al, Human Cord Blood Cells as Targets for Gene Transfer, J. Exp. Med., vol. 178, Aug., 1993, 529-536.
Kohn et al, Retroviral Vector Mediated Gene Transfer into Primitive Human Hemetopoietic Progenitor Cells, Exp Hematol. 20 : 1065-71 (1992).
Marshall, Science, 269, 1995, 1050-1055.
Uhlmann et al., Chem. Rev. 90(4): 544-588, 1990.
Milligan et al., J. Med. Chem. 36(14): 1924-1937, 1992.
Oakin et al., “NIH Report and Recommendations”, Dec. 7, 1995 1-40.
Kohn et al. Nat. Med. 1(10): 1017-1023, 1995.
Culver, “Gene Therapy—A Handbook for Physicians” 1994, pp. 1-117.
Orkin and Motulsky, 1995, “Report and Recommendationof the panel to assess the NIH investment in research on Gene therapy”, NIH, Dec. 7, 1995.
Moore, 1993, Journal of Hematotherapy, 2(2):221-224, Aug. 1993.
Miller, et al.,Biotechniques, vol. 7, No. 9, pp. 980-990 (1989).
Hock, et al.,Blood, vol. 74, No. 2, pp. 876-881 (Aug. 1, 1989).
Moritz, et al.,J. Exp. Med., vol. 178, pp. 529-536 (Aug., 1993).
Blaese R. Michael
Kohn Donald B.
Moen Robert C.
Mullen Craig A.
Children's Hospital of LosAngeles
Lillie Raymond J.
Olstein Elliot M.
The United States of America as represented by the Department of
Wehbe Anne M.
LandOfFree
Gene therapy by administration of genetically engineered... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene therapy by administration of genetically engineered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene therapy by administration of genetically engineered... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3540144